Article info

Download PDFPDF

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

Authors

  1. Correspondence to Dr Sam E Mansour, Virginia Retina Center, 45 North Hill Drive, Suite 202, Warrenton, VA 20186, USA; sm{at}virginiaretina.com
View Full Text

Citation

Mansour SE, Kiernan DF, Roth DB, et al
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

Publication history

  • Received February 3, 2020
  • Revised April 7, 2020
  • Accepted April 21, 2020
  • First published May 27, 2020.
Online issue publication 
February 18, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.